127 related articles for article (PubMed ID: 26106008)
1. Double-Hit Lymphoma.
Goyal G; Caponetti GC; Silberstein PT
J Clin Exp Hematop; 2015; 55(1):51-3. PubMed ID: 26106008
[No Abstract] [Full Text] [Related]
2. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
3. [Significance and application of c-myc in diffuse large B-cell lymphoma].
Huang WT; Lü N; Guo L
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):638-40. PubMed ID: 24314257
[No Abstract] [Full Text] [Related]
4. A rare MYC/BCL3 double-translocation and protein-expression in a diffuse large B-cell lymphoma.
Ohno H; Nakagawa M; Kishimori C; Fukutsuka K; Hayashida M; Izumi K; Akasaka T; Honjo G; Haga H
Leuk Lymphoma; 2019 Mar; 60(3):825-828. PubMed ID: 30187810
[No Abstract] [Full Text] [Related]
5. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
6. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
[TBL] [Abstract][Full Text] [Related]
7. Diffuse swelling of the buccal mucosa and palate as first and only manifestation of an extranodal non-Hodgkin 'double-hit' lymphoma: report of a case.
Frei M; Dubach P; Reichart PA; Schmitt AM; Mueller-Garamvölgyi E; Bornstein MM
Oral Maxillofac Surg; 2012 Mar; 16(1):69-74. PubMed ID: 20981461
[TBL] [Abstract][Full Text] [Related]
8. Double-hit diffuse large B-cell lymphoma.
Friedberg JW
J Clin Oncol; 2012 Oct; 30(28):3439-43. PubMed ID: 22949152
[No Abstract] [Full Text] [Related]
9. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
[TBL] [Abstract][Full Text] [Related]
10. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.
Kobayashi T; Tsutsumi Y; Sakamoto N; Nagoshi H; Yamamoto-Sugitani M; Shimura Y; Mizutani S; Matsumoto Y; Nishida K; Horiike S; Asano N; Nakamura S; Kuroda J; Taniwaki M
Jpn J Clin Oncol; 2012 Nov; 42(11):1035-42. PubMed ID: 22984125
[TBL] [Abstract][Full Text] [Related]
11. Double-hit vitreoretinal lymphoma.
Or C; Kirker AW; Rasmussen S; Villa D; Gerrie AS; Forooghian F
Can J Ophthalmol; 2014 Jun; 49(3):e73-6. PubMed ID: 24862789
[No Abstract] [Full Text] [Related]
12. Double hit, triple hit--look for it.
Benz R; Tchinda J
Blood; 2013 Mar; 121(13):2383. PubMed ID: 23658934
[No Abstract] [Full Text] [Related]
13. [Clinicopathological and molecular genetic characteristics of childhood diffuse large B cell lymphoma].
Huang H; Yang WP; Xu HY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):209-11. PubMed ID: 22780976
[No Abstract] [Full Text] [Related]
14. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
15. MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?
Thieblemont C; Brière J
Blood; 2013 Mar; 121(12):2165-6. PubMed ID: 23520325
[No Abstract] [Full Text] [Related]
16. Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.
Friedberg JW
Chin Clin Oncol; 2015 Mar; 4(1):9. PubMed ID: 25841716
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy.
Tumati V; Trivedi L; Li HC; Patel P; Scaglioni PP; Vusirikala M; Sadeghi N; Rizvi S; Chen W; Wachsmann J; Collins R; Desai NB
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1126-1132. PubMed ID: 29722657
[TBL] [Abstract][Full Text] [Related]
18. Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome.
Caponetti GC; Dave BJ; Perry AM; Smith LM; Jain S; Meyer PN; Bast M; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Aoun P; Fu K; Greiner TC; Chan WC; Sanger WG; Weisenburger DD
Leuk Lymphoma; 2015; 56(11):3082-9. PubMed ID: 25827211
[TBL] [Abstract][Full Text] [Related]
19. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
Dunleavy K
Curr Treat Options Oncol; 2015 Dec; 16(12):58. PubMed ID: 26634708
[TBL] [Abstract][Full Text] [Related]
20. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
